O Orexo AB
O
Open
20.9 8.52
Übersicht
Veränderung der Aktienkurses
24h
Min
19.24
Max
20.95
Einkommen | 41M -75M |
|---|---|
Verkäufe | 1.7M 5M |
EPS | -3.812 |
Gewinnspanne | -1,500 |
Angestellte | 65 |
EBITDA | 206M -66M |
Nächstes Ergebnis | 16. Juli 2026 |
|---|
Marktkapitalisierung | -35M 665M |
|---|---|
Vorheriger Eröffnungskurs | 12.38 |
Vorheriger Schlusskurs | 20.9 |
Orexo AB Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
